Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.

ABSTRACT: Importance:When a novel drug is granted accelerated approval, both its on-label and off-label uses must be taken into account. Objectives:To estimate the potential upper bound of off-label use of erdafitinib to treat advanced cancer with fibroblast growth factor receptor gene (FGFR) alterations, compare it to the upper bound of on-label use in urothelial cancer, and to review studies that may support off-label use. Design, Setting, and Participants:This cross-sectional study used frequency data on FGFR alterations by cancer type and the estimated number of deaths from all cancers for 2019 in the United States. Mortality statistics were used as surrogates for patients with advanced cancer. Analysis was conducted in May 2019. Exposure:Percentage of patients with an FGFR2 or FGFR3 alteration. Main Outcomes and Measures:Estimated number of patients with advanced cancer expressing an FGFR2 or FGFR3 alteration eligible for off-label use of erdafitinib by cancer type; number of studies investigating FGFR-targeting drugs for patients with cancer; and number of ongoing clinical trials on erdafitinib by cancer type. Results:A total of 15 cancer types had reported FGFR alterations. Of 455?440 estimated patients who died of cancer in 2019, 17?019 (3.7%) were estimated to have FGFR2 or FGFR3 alterations. Of these patients, 12?955 (76.1%) could be eligible for off-label treatment with erdafitinib. A total of 29 completed studies evaluated FGFR-targeting drugs in 11 cancer types, and 10 ongoing studies are studying erdafitinib for different oncological indications. Conclusions and Relevance:This study indicates that the potential for off-label use of FGFR inhibitors such as erdafitinib spans a number of cancer types and a large patient population. Systematic trials exploring off-label uses may be desirable for drugs that target clear, identifiable molecular alterations because this may be more efficient than off-label use in identifying clinical scenarios where the agent has activity.

SUBMITTER: de Almeida Carvalho LM 

PROVIDER: S-EPMC6902826 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature